Reviewed listing: NASDAQ:PAYS · Analysis dated Oct 16, 2026
It has not been confirmed whether the basis of this analysis still holds today. Read it as a dated earlier assessment; it does not establish a current buying opportunity.
How does the company make money?
Paysign processes payments to plasma donors and administers programs through which pharmaceutical companies help patients with medication costs. The company earns revenue, among other things, from setting up, administering, and processing these programs.
What supports the business?
Paysign is not just growing; it is earning significantly more from its ongoing business. Even without a one-time accounting gain, operating income as a share of revenue rose to 21.3 percent in the second quarter.
What could improve?
Additional drug assistance programs could make better use of the existing platform and further increase earnings. The key is that they generate lasting available cash surpluses, not just higher accounting profits.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
15.60 USD appear expensive despite the substantial business improvement: Even if the company meets its forecast, investors are paying about 42 to 45 times expected annual earnings per share. I am therefore not yet convinced by the balance between price and risks.
What is the main risk?
The high stock price requires consistently strong earnings, while changes to medication assistance programs and customer losses could hamper the business. In addition, the latest earnings benefited from a one-time accounting gain and a lower tax rate.
What is the overall assessment?
Paysign is convincingly improving its operating earnings power. However, at the specified price of 15.60 USD, much enduring success is already assumed; therefore, the stock remains on the watchlist.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign inSources used in the analysis
- Original source 1 · api-v4.fcsapi.com
- Original source 2 · data.sec.gov
- Original source 3 · data.sec.gov
- Original source 4 · www.sec.gov · Mar 25, 2026
- Original source 5 · www.sec.gov · Aug 06, 2026
- Original source 6 · www.sec.gov · Aug 05, 2026
- Original source 7 · www.sec.gov · Apr 03, 2020
- Original source 8 · paysign.com · Oct 13, 2026